Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Renee Ackley"'
Autor:
Michaele Phan, Jacqueline Meredith, Renee Ackley, Alex Ebeid, Kristen Goodrich, Mindy Sampson
Publikováno v:
Open Forum Infectious Diseases. 9
Background Available studies assessing the efficacy of beta-lactam antibiotics compared to vancomycin (VAN) in the treatment of Enterococcal blood stream infections (BSI) have varying results and have not assessed the impact of rapid diagnostic testi
Publikováno v:
The Journal of Pediatric Pharmacology and Therapeutics. 24:421-430
OBJECTIVES Accurate determination of ideal body weight (IBW) in pediatric patients is important for the proper dosing of many medications and the classification of nutritional status. There is no consensus on the best method to calculate IBW. The pur
Autor:
Christopher Polk, William E. Anderson, Sarah Brooks Minor, Gerald A. Capraro, Danya Roshdy, Renee Ackley, Jacqueline Meredith
Publikováno v:
Antimicrobial Agents and Chemotherapy. 64
The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections remains unknown. This was a multicenter, retrospective cohort study of adults with CRE infections wh
Autor:
Renee, Ackley, Danya, Roshdy, Jacqueline, Meredith, Sarah, Minor, William E, Anderson, Gerald A, Capraro, Christopher, Polk
Publikováno v:
Antimicrob Agents Chemother
The comparative efficacy of ceftazidime-avibactam and meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections remains unknown. This was a multicenter, retrospective cohort study of adults with CRE infections wh
Publikováno v:
Open Forum Infectious Diseases
Background There is little data on the comparative efficacy or safety of carbapenem-resistant Enterobacterales (CRE)-targeted beta-lactam beta-lactamase inhibitors (BL-BLI), including ceftazidime/avibactam (CZA) and meropenem/vaborbactam (MVB), versu
Autor:
Renee Ackley, Gerald A. Capraro, Jacqueline Isip, Danya Roshdy, Sarah Brooks Minor, Christopher Polk, William E Anderson, Amanda L Elchynski
Publikováno v:
Open Forum Infectious Diseases
Background Options for treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections were historically limited to antibiotics with limited efficacy and significant toxicities. Ceftazidime/avibactam (CA) and meropenem/vaborbactam (MV) are supe